Sinovac Says Nasdaq Panel Grants its Request to Continue Listing

Sinovac Biotech announces that the Nasdaq Hearings Panel has granted the company’s request to continue its listing on the Nasdaq Stock Market, subject to conditions focused on timely completion of its financial audit and remediation of filing delinquencies, according to a statement.

• Sinovac says it is working with its accounting firm to complete the required audit and to regain compliance with its filing obligations by May 11

To contact the reporter on this story:
Upmanyu Trivedi in London at utrivedi2@bloomberg.net

To contact the editors responsible for this story:
Sachin Ravikumar at sravikumar6@bloomberg.net

Olivia Tam

© 2026 Bloomberg L.P. All rights ...